Navigation Links
KV Begins Shipping Evamist(TM) to Wholesalers
Date:4/14/2008

s, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation; (14) completion of the Company's financial statements for the first, second and third quarters of fiscal 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; (16) the risks detailed from time to time in the Company's filings with the Securities and Exchange Commission; and (17) the impact of credit market disruptions on the fair value of auction rate securities that we h
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. When a Mind Begins to Disappear: A Young Familys Journey to the Dark Side
2. Annual National Public Health Week Begins Today
3. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
4. As Congress Begins Debate on Bush Budget, Front-Line Caregivers Urge Rejection of Medicare Cuts
5. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
6. High blood pressure worsening in all states for women; begins to stagnate for men
7. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
8. USA TODAY to Report Special Series "Turning 62: The Retirement Boom Begins"
9. Fitness Begins at Home
10. Work Begins on New Regional Hospital Medical Campus
11. Johnson City Medical Center Begins Offering Einstein Bros. Menu Items at Second On Campus Location
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...her to stop abusive behavior, experts say , ... that was once dismissed as "kids being kids" is n...search shows the negative effects on both the bull...ools, parents and even kids themselves are coming ...or. , "Bullying shouldn,t be considered a norm...
(Date:11/21/2008)...as Health Science Center at Houston will launch a ...(TEXAS), to promote geriatrics training for physic...he Donald W. Reynolds Foundation and $1.25 million... geriatric medicine principles to everyone from th...ians. With the reach of Lyndon B. Johnson General ...
(Date:11/21/2008).../ -- The Providence Service,Corporation (Nasdaq: ... Company,s,Chief Operating Officer, has been appo...orris, appointment fills the vacancy left by the A...eturns the board to six members. Mr.,Norris will... Mr. Norris, age 41, has been with Providence sinc...
(Date:11/21/2008)...t Lennox-Gastaut syndrome , , FRIDAY, No... (rufinamide) has been approved as a supplementary...nnox-Gastaut syndrome, the U.S. Food and Drug Admi... based on results of a four-month clinical trial t...tients who took a placebo, those who took the drug...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...a Health Minister was issued notice after a compla...hange for arranging transfers // and appointment...d Wayanad. Lok Ayukta Justice K Sreedharan and Up...ssued the notice on Wednesday against K.K. Ramacha...
...rials conducted on Rotateq and Rotarix in more tha...ion of childhood diarrhea. The vaccines have been ... The dreadful disease accounts for 1/3rd of all ho...e had been developed for the disease during the 19...
...rmacies have handed out over 6,000 chlamydia testi...t scheme aimed at tackling the silent sex disease....ing Program which last year revealed as many as on...the disease. The trial was launched in November to...
...ngdom Ministry is planning for reduction of waitin...gery. The Government is planning to reduce the non... from time of admission to NHS. Government is hopi... 2008. Patients wait for long time for initial app...
Other Medicine News:Health News:Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection 2
(Date:11/20/2008)...ON, Nov. 20 PAREXEL Inte... global biopharmaceutical services provider, today...eru to provide regulatory consulting and clinical ...ru office, PAREXEL now has locations throughout fi...erica, which also include Argentina, Brazil, Chile...
(Date:11/19/2008)...FRANCISCO, Nov. 19 Posit Science C...ence at the Society for Neuroscience,Annual Confe...cognitive,training may benefit Baby Boomers. The...s Program (TM) uses adaptive exercises that target...e designed to drive generalized,improvements in c...
(Date:11/19/2008)... , Study did not achieve statistical signific...-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS...cal trial of its topical NanoEmulsion (NE) drug de...ethanolamine. , , The multi-center, randomi...uated the safety and efficacy of the Company,s 3% ...
(Date:11/19/2008)...ROCHELLE, N.Y., Nov. 19 Biotech sc...logies to toxicology research to better understand... of organ systems, reports Genetic Engineering &a...ly interested in figuring out a new compound,s mec...ctive toxicology technique, according to the Novem...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Linnartz New Head of Investor Relations of Gerresheimer 5722 1Scientists enhance Mother Natures carbon handling mechanism 1135 1Scientists enhance Mother Natures carbon handling mechanism 1135 2Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 1Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 2Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 3Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 4Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 5Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 6Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 7Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 8Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 9Providence Service Corporation Announces 35 25 Revenue Growth with Third Quarter Results 3B Increases Revenue Guidance for 2007 5714 10PharmAthene to Webcast its Third Quarter Conference Call on November 13 2007 at 4 3A30 P M Eastern Time 780 1PharmAthene to Webcast its Third Quarter Conference Call on November 13 2007 at 4 3A30 P M Eastern Time 780 2
...BOSTON--(BUSINESS WIRE)--May 3, 2007 - New data sh...ed reduction of chorea,associated with Huntington,...o successfully completed treatment in a 13-week tr...used successfully to,sustain reduced chorea burden...e potential benefit of,tetrabenazine as maintenanc...
...KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - N...ed that a combination of,COPAXONE(R) (glatiramer a...inocycline reduced T1 Gadolinium (Gd)-enhancing le...nts with active,relapsing-remitting multiple scler...ging (MRI), compared to those receiving,COPAXONE(R...
Other Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
The LH 755 simplifies and automates high-volume hematology testing by integrating expert automation and advanced technologies into one workcell. It delivers reliable, accurate results every time. Plu
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C.
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents.
Medicine Products: